AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05203588
Drug: calcium and vitamin D
RxNorm normalized name: Wellesse Calcium and Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium (≥1·0 g) and vitamin D (≥400 IU).
Trial: NCT05993975
Drug: Bupivacain 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride was given without any adjuvant
Trial: NCT06467344
Drug: ACDN-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Trial: NCT05280873
Drug: Pirfenidone, methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
Trial: NCT05477576
Drug: RYZ101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP3D as determined in Phase 1b
Trial: NCT05088876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded withdrawal of regular co-medication with paracetamol
Trial: NCT06787144
Drug: ELVN-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once daily
Trial: NCT06634849
Drug: PTT-4256
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg.
Trial: NCT05802394
Drug: Later-line therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Trial: NCT06785636
Drug: Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pocenbrodib alone or in combination
Trial: NCT05230758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
Trial: NCT05421416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar pill
Trial: NCT06271174
Drug: Profofol and/or Suxaméthonium and/or Sévoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics.
Trial: NCT05957432
Drug: Black Seed Oil Cap/Tab
RxNorm normalized name: BLACK SEED OIL CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
Trial: NCT05957432
Drug: Vonoprazan, Amoxicillin and Clarithromycin
RxNorm normalized name: vonoprazan, amoxicillin and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori vonoprazan based treatment
Trial: NCT06494943
Drug: IBI110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAG-3 inhibitor
Trial: NCT06126666
Drug: ABL103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Trial: NCT05462353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered orally once daily.
Trial: NCT05423691
Drug: CK0804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
Trial: NCT05184192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose monohydrate NF
Trial: NCT04513821
Drug: Mino-Lok Therapy (MLT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
Trial: NCT05765981
Drug: VGN-R09b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
Trial: NCT05156398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo 75mg or 50mg (2 X 25mg) ODT
Trial: NCT06040320
Drug: CHP
RxNorm normalized name: TRACH SPEAKING VALVE,TRACHPHONE #7707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
Trial: NCT06484062
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05826535
Drug: IMPT-314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR T-cell therapy
Trial: NCT04888741
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post transplant cyclophosphamide strategy for GVHD prophylaxis
Trial: NCT06798246
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemicitabin and cisplatin
Trial: NCT06798246
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1
Trial: NCT05480774
Drug: Placebo hard capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject was given orally 2 placebo hard capsules/day for 12 weeks
Trial: NCT06234345
Drug: Comparator - Trimbow®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this group will receive 2 triggering twice a day
Trial: NCT05599919
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Trial: NCT04380545
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06037031
Drug: Drug: PF-07923568
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07923568 administered orally as 4 capsules
Trial: NCT04867434
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small synthetic molecule for submental fat reduction
Trial: NCT04867434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04741139
Drug: Acetaminophen and Diphenhydramine Only Product
RxNorm normalized name: Acetaminophen and diphenhydramine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
Trial: NCT06085742
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/m2 PO once a day (21 continuous days)
Trial: NCT06085742
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/m2 PO BID on days 1, 8, and 15
Trial: NCT06085742
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825mg/m2 PO BID on days 1-14
Trial: NCT05146739
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Give PO or IV
Trial: NCT05146739
Drug: Triple Intrathecal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT06460987
Drug: RAS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive RAS inhibitor treatment as specified in the KDIGO guidelines
Trial: NCT06460987
Drug: Immune Suppressant
RxNorm normalized name: IMMUNE SUPPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive immune suppressant treatment as specified in the KDIGO guidelines
Trial: NCT06109779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV (intravenous) Q3W
Trial: NCT06109779
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Trial: NCT04650269
Drug: Biktarvy 50Mg-200Mg-25Mg Tablet
RxNorm normalized name: Biktarvy 50mg-200mg-25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
Trial: NCT05398679
Drug: Clindamycin Injection
RxNorm normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg/8 hours (maximum 1.800 mg x day) IV
Trial: NCT05398679
Drug: Rifampicin Only Product in Oral Dose Form
RxNorm normalized name: Rifampicin only product in oral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,3-0,5 g/12 hours (maximum 1200 mg x day)
Trial: NCT05398679
Drug: Rifampicin Only Product in Parenteral Dose Form
RxNorm normalized name: Rifampicin only product in parenteral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,3-0,6 g/12 hours (maximum 1200 mg x day)
Trial: NCT05935761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as active comparator arms, except placebo dispensed
Trial: NCT05193396
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hydrocortisone
Trial: NCT05087992
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI
Trial: NCT06468280
Drug: XELOX Chemotherapy Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle.
Trial: NCT06073665
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine dose will depend on dose at baseline and randomization group
Trial: NCT05758922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT05869955
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05106296
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Trial: NCT05624749
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo s.c. monthly
Trial: NCT05107674
Drug: NX-1607
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NX-1607
Trial: NCT05011019
Drug: AL2846 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor.
Trial: NCT06232577
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05140382
Drug: AZD4573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4573 will be given intravenously
Trial: NCT04031066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion i.v. treatment
Trial: NCT05526742
Drug: CKD-510 tablet (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
Trial: NCT05526742
Drug: CKD-510 tablet (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of CKD-510 will be administered as oral tablet in a fed state.
Trial: NCT06375993
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy for Lymphodepletion
Trial: NCT06030622
Drug: C3 (Metformin, Simvastatin, and Digoxin) only
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
Trial: NCT05669755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
Trial: NCT05084235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matches the active drug in appearance, odor and labelling
Trial: NCT06379425
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Trial: NCT06379425
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Trial: NCT06168461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT06630234
Drug: DCC-3009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05806346
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) intravenous administration
Trial: NCT05540860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally once per day
Trial: NCT05040321
Drug: MIB-626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
Trial: NCT05040321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive either the placebo or 1000 mg MIB-626 twice daily orally.
Trial: NCT03560583
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg BID
Trial: NCT05449132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Trial: NCT04748588
Drug: Anti-SARS-CoV-2 mAb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used.
Trial: NCT05738148
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC.
Trial: NCT05249777
Drug: TD0069 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
Trial: NCT04802967
Drug: Ketoprofen Lysine Salt combined with Gabapentin
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
Trial: NCT04802967
Drug: Ketoprofen Lysine Salt
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
Trial: NCT06798376
Drug: ≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
Trial: NCT06798376
Drug: ≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
Trial: NCT04971733
Drug: E2814
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2814 intravenous infusion.
Trial: NCT05081609
Drug: TransCon IL-2 β/γ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
Trial: NCT05081609
Drug: TransCon TLR7/8 Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
Trial: NCT04825171
Drug: Bryophyllum 50 % Chewing Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
Trial: NCT06321289
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
Trial: NCT04945161
Drug: ON101 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Trial: NCT06304545
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine PO oxaliplatin IV
Trial: NCT06186401
Drug: Cyclophosphamide (non-investigational)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06056297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered per schedule specified in the arm description.
Trial: NCT05944224
Drug: SPH4336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
Trial: NCT06687369
Drug: MB12 (Proposed Pembrolizumab Biosimilar)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV, every 3 weeks on Day 1
Trial: NCT06687369
Drug: EU-sourced Keytruda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV, every 3 weeks on Day 1
Trial: NCT06687369
Drug: US-sourced Keytruda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV, every 3 weeks on Day 1
Trial: NCT05016076
Drug: Placebo (0.9% sodium chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
Trial: NCT05180526
Drug: QLETLI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Trial: NCT06217185
Drug: Taxanes
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxanes: Usual clinical dose is administered, in a 21-day cycle.
Trial: NCT06217185
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 650mg/m2 each time, given twice daily
Trial: NCT04655755
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05962606
Drug: AON-D21
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Trial: NCT05962606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.